Cabaletta Bio, Inc. (CABA) Analyse boursière

Présentation de l'entreprise

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology entity dedicated to the discovery and development of engineered T cell therapies specifically targeted at patients suffering from autoimmune diseases. The company functions within the healthcare sector, with its operational focus situated in the biotechnology industry, a domain characterized by high research intensity and significant capital requirements for product advancement. The enterprise maintains a market capitalization of 343.99 millions of dollars, employs a workforce of 154 individuals, and reports no available revenue data for the trailing twelve-month period. These valuation and personnel metrics indicate that the company is a small-cap entity in the biotech space, relying on future clinical milestones and regulatory approvals to generate substantial revenue streams rather than current sales performance.

Santé financière

For the trailing twelve-month period, the company reports a net income of negative 167.86 millions of dollars and an EBITDA of negative 170.60 millions of dollars, with revenue data listed as not available. The substantial gap between the reported net income and EBITDA figures, alongside the absence of revenue, highlights a cost structure driven primarily by research and development expenditures rather than operational inefficiencies relative to sales. Free cash flow stands at negative 81.28 millions of dollars, indicating that the company is currently burning cash to fund its clinical programs and that it lacks immediate financial flexibility to sustain operations without further capital raising. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure consistent with clinical-stage biotechnology firms that have not yet achieved commercial product launches or sustained profitability. The balance sheet holds cash reserves of 133.60 millions of dollars against total debt of 27.10 millions of dollars, resulting in a debt-to-equity ratio of 24.18. Despite the leverage indicated by the debt-to-equity ratio, the cash position significantly exceeds debt obligations, suggesting a conservative liquidity stance typical of pre-revenue biotech assets. The current ratio is 2.77, which indicates that the company possesses strong short-term liquidity relative to its current liabilities, ensuring it can meet immediate obligations. Return on Equity is negative 127.0% and Return on Assets is negative 61.5%, metrics that reveal management is currently utilizing shareholder capital and assets to fund loss-making operations rather than generating immediate returns.

Évaluation de la valorisation

The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E ratio is recorded at negative 2.20, implying that the market expects earnings to remain negative or turn positive in the future, preventing a traditional multiple comparison. The price-to-book ratio stands at 2.77, indicating that the market values the company at a premium of 177% over its net asset book value, a common valuation characteristic for companies with significant intellectual property and potential future cash flows. Price-to-sales and EV/EBITDA metrics are also not available or negative (EV/EBITDA at -1.39), suggesting that traditional sales-based or earnings-based valuation models are not applicable in the standard sense for a firm with no revenue and negative earnings. The stock has traded between a 52-week high of 3.78 and a 52-week low of 1.01, meaning the current valuation sits within this established volatility range without reaching the upper historical extreme. The beta value is 3.29, which signifies that the stock exhibits high price volatility and is expected to move with significantly greater magnitude than the broader market index.

Growth & Income

Revenue growth and earnings growth for the year-over-year period are not available due to the lack of historical revenue data and current profitability. Since the company does not pay dividends, the dividend yield and payout ratio are both not available or zero, confirming that all available earnings are theoretically reinvested into research and development rather than distributed to shareholders. As a non-dividend payer, Cabaletta Bio directs its limited financial resources entirely toward sustaining clinical trials and expanding its pipeline of engineered T cell therapies rather than providing income to investors. Consequently, the overall growth and income profile is defined by a reliance on future capital markets access to fund growth, with no current income generation to support shareholder returns.